Another month has come and gone, and with it, several FDA approvals and regulatory updates related to the ever-evolving landscape of pediatric health care. In our March monthly recap, we list our top ...

Fathers who took 2 or more weeks of leave after the birth of their infant were more likely to report longer breastfeeding duration. A study published in BMC Health found that fathers who took 2 or ...

Jay T. Rubinstein, MD, PhD, emphasized that children with hearing loss should receive genetic testing, as the investigational DB-OTO gene therapy demonstrated positive results. Regeneron ...

A surprise mimicker of a rare disorder: 13-year-old female with altered mental status ...

On March 31, 2025, Ascendis Pharma A/S announced it has submitted a new drug application (NDA) to the FDA for navepegritide (TransCon CNP) to treat children with achondroplasia. 1 In a press release ...

Our editorial advisory board member Donna Hallas, , PPCNP-BC, CPNP, PMHS, FAANP, FAAN, highlights an article published in the March issue of Contemporary Pediatrics. Many parents may be using at-home ...

In 2021, the American Academy of Pediatrics, American Academy of Child and Adolescent Psychiatry, and the Children’s Hospital Association jointly declared a national emergency in child and adolescent ...

Pediatric cancer survivors can be vulnerable to cardiovascular disease in the short- or long-term with increased recognition of cardiotoxic cancer treatments, as 5-year survival rates for children are ...

Mesoblast's remestemcel-L (Ryoncil) was approved by the FDA on December 18, 2024 to treat SR-aGVHD in patients 2 months and older. Now, it is available for purchase. The FDA-approved allogeneic (donor ...

Fitusiran is administered subcutaneously starting once every 2 months for patients aged 12 years and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors. The FDA has ...

With 1 in 7 adolescents worldwide diagnosed with mental health disorders, emerging research suggests that diet is a powerful yet often overlooked therapeutic tool. Adolescence brings a perfect storm ...

A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments. As we transition into the second ...